FDA approves a new Alzheimer's drug. What to know about Eli Lilly's Kisunla
The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.
FDA approves donanemab, now Kisunla, to treat early Alzheimer’s
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion respectively by 2030.
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD),
FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
The FDA today approved Eli Lilly’s Kisunla™ (donanemab-azbt), a once-monthly treatment for adults with early Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the progress of the disease. The treatment, which is called donanemab and will be sold under the brand name Kisunla, is a monthly IV infusion.
FDA approves Alzheimer's drug Kisunla from Eli Lilly
The Food and Drug Administration has approved a new drug to treat Alzheimer's after trials found it slowed the decline of memory and thinking skills in patients with the disease.
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
An advisory committee to the Food and Drug Administration on Monday endorsed an Alzheimer’s drug made by Eli Lilly, setting the stage for the agency to approve another medication that has shown it can slow the progression of the disease.
U.S. Regulator Approves Eli Lilly's Alzheimer's Drug
The U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Eli Lilly's (LLY) Alzheimer's drug called "Donanemab." Eli Lilly's medication for early-stage Alzheimer's disease is one of only a few treatment options available for the brain disease and is expected to provide the company with blockbuster sales.
Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
Eli Lilly's (LLY) new Alzheimer's drug Kisunla could generate peak sales of up to $7.1B, diversifying the drugmaker's revenue stream, according to analysts. Read more here.
BMO: Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Could Boost Sales by $7.1B
Shares of Eli Lilly (NYSE:LLY) fell in today’s trading despite receiving some analyst praise. According to BMO, via four-star analyst Evan
WOOD Grand Rapids on MSN5h
FDA approves another Alzheimer’s drug that can modestly slow disease
The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by ...
Monthly Prescribing Reference4d
Kisunla Approved for Early Symptomatic Alzheimer Disease
The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.
Eli Lilly’s Kisunla Approval Spurs Buy Rating Amid Anticipated Revenue Boost and Alzheimer’s Treatment Paradigm Shift
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Arabian Business4d
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
Eli Lilly said a year’s worth of Kisunla therapy would cost $32,000 in the US ($48,696 for 18 months) Eli Lilly’s Kisunla ...
Zacks.com on MSN2d
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly LLY won a long-awaited FDA approval for its Alzheimer's disease (AD) drug, donanemab, to be sold under the brand ...